Age-dependent ferritin elevations and HFE C282Y mutation as risk factors for symptomatic knee osteoarthritis in males: a longitudinal cohort study

BMC Musculoskeletal Disorders

Steven B Abramson¹  Xi Huang³  Jeffrey D Greenberg³  Jonathan Samuels³  Svetlana Krasnokutsky³  Cheongeun Oh²  Mukundan Attur³  Lauren Kennish³ 

[1] Division of Rheumatology, NYU Hospital for Joint Diseases, 301 East 17th Street, Suite 1410, New York, NY 10003, USA;Department of Population Health, Division of Biostatistics, New York University School of Medicine, New York, NY, USA;Division of Rheumatology, Department of Medicine, New York University School of Medicine, NYU Hospital for Joint Diseases, New York, NY, USA

关键词: Hypoxia inducible factor;    Hemochromatosis;    Radiographic progression;    Iron;    Osteoarthritis;   

Others  :  1128951
DOI  :  10.1186/1471-2474-15-8

 received in 2013-08-27, accepted in 2013-12-11,  发布年份 2014

【 摘 要 】

Background

Age, gender and genetic predisposition are major intrinsic risk factors for osteoarthritis (OA). Iron increases are associated with age and gene mutation. In the present study, we examined whether serum ferritin, an indicator of total body iron stores, correlates with clinical features in patients with OA, and whether the hemochromatosis Fe (HFE) gene mutation plays a role.

Methods

In a 2-year longitudinal observational study, 127 patients with knee OA and 20 healthy individuals (controls) were enrolled. All patients underwent standardized weight-bearing fixed-flexion posteroanterior knee radiographs. Peripheral blood samples were analyzed for serum ferritin, and genotyped for HFE using allelic discrimination methods.

Results

Higher levels of serum ferritin were found in patients older than 56 years (P =0.0186) and males (P =0.0006), with a trend toward higher ferritin in patients with OA. HFE gene mutation carriers were more prevalent among patients with OA than among healthy controls. When stratified further by gender, we found that male patients with OA had higher levels of serum ferritin than male control subjects [odds ratio = 4.18 (limits of 95% confidence interval: 0.86–27.69, P = 0.048)]. Analyses of radiographic data indicated that higher ferritin was associated with narrower joint space width at baseline (P = 0.032) in male patients. Additionally, among men, risk prediction of radiographic severity [Kellgren-Lawrence (KL) grade >2)] in the higher ferritin group was almost five times that of the lower ferritin group (odds ratio = 4.74, P = 0.023).

Conclusion

Our data suggest that increased ferritin levels are associated with symptomatic knee OA in males. This finding needs to be validated in a larger cohort of patients.

【 授权许可】

   
2014 Kennish et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al.: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008, 58(1):15-25.
• [2]Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA: Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum 2009, 60(12):3546-3553.
• [3]Samuels J, Krasnokutsky S, Abramson SB: Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 2008, 66(3):244-250.
• [4]Abramson SB, Attur M: Developments in the scientific understanding of osteoarthritis. Arthritis Res Ther 2009, 11(3):227. BioMed Central Full Text
• [5]Goldring MB, Goldring SR: Osteoarthritis. J Cell Physiol 2007, 213(3):626-634.
• [6]Zeleniuch-Jacquotte A, Zhang Q, Dai J, Shore RE, Arslan AA, Koenig KL, et al.: Reliability of serum assays of iron status in postmenopausal women. Ann Epidemiol 2007, 17(5):354-358.
• [7]Ali MA, Akhmedkhanov A, Zeleniuch-Jaquotte A, Toniolo P, Frenkel K, Huang X: Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women. Cancer Detect Prev 2003, 27(2):116-121.
• [8]Jian J, Pelle E, Huang X: Iron and menopause: does increased iron affect the health of postmenopausal women? Antioxid Redox Signal 2009, 11(12):2939-2943.
• [9]Cairo G, Recalcati S: Iron-regulatory proteins: molecular biology and pathophysiological implications. Expert Rev Mol Med 2007, 9(33):1-13.
• [10]Milman N, Pedersen P, Steig T, Byg KE, Graudal N, Fenger K: Clinically overt hereditary hemochromatosis in Denmark 1948–1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 2001, 80(12):737-744.
• [11]Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM: Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000, 140(1):98-104.
• [12]Weiss G: Genetic mechanisms and modifying factors in hereditary hemochromatosis. Nat Rev Gastroenterol Hepatol 2010, 7(1):50-58.
• [13]Hanson EH, Imperatore G, Burke W: HFE gene and hereditary hemochromatosis: a HuGE review. Human genome epidemiology. Am J Epidemiol 2001, 154(3):193-206.
• [14]Phatak PD, Sham RL, Raubertas RF, Dunnigan K, O’Leary MT, Braggins C, et al.: Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med 1998, 129(11):954-961.
• [15]Valdes AM, Spector TD: The genetic epidemiology of osteoarthritis. Curr Opin Rheumatol 2010, 22(2):139-143.
• [16]Carroll GJ, Sharma G, Upadhyay A, Jazayeri JA: Ferritin concentrations in synovial fluid are higher in osteoarthritis patients with HFE gene mutations (C282Y or H63D). Scand J Rheumatol 2010, 39(5):413-420.
• [17]Yazar M, Sarban S, Kocyigit A, Isikan UE: Synovial fluid and plasma selenium, copper, zinc, and iron concentrations in patients with rheumatoid arthritis and osteoarthritis. Biol Trace Elem Res 2005, 106(2):123-132.
• [18]Roosendaal G, van Rinsum AC, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW: Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology 1999, 34(2):144-153.
• [19]Carroll GJ: Primary osteoarthritis in the ankle joint is associated with finger metacarpophalangeal osteoarthritis and the H63D mutation in the HFE gene: evidence for a hemochromatosis-like polyarticular osteoarthritis phenotype. J Clin Rheumatol 2006, 12(3):109-113.
• [20]Loughlin J, Carr A, Chapman K: The common HFE variants C282Y and H63D are not associated with primary OA of the hip or knee. J Rheumatol 2005, 32(2):391-392.
• [21]Sahinbegovic E, Dallos T, Aigner E, Axmann R, Engelbrecht M, Schoniger-Hekele M, et al.: Hereditary hemochromatosis as a risk factor for joint replacement surgery. Am J Med 2010, 123(7):659-662.
• [22]Sahinbegovic E, Dallos T, Aigner E, Axmann R, Manger B, Englbrecht M, et al.: Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum 2010, 62(12):3792-3798.
• [23]Hooiveld MJ, Roosendaal G, van den Berg HM, Bijlsma JW, Lafeber FP: Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: an in vitro study. Rheumatology (Oxford) 2003, 42(6):784-790.
• [24]Muller M: Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal 2009, 11(1):59-98.
• [25]Muckenthaler MU, Galy B, Hentze MW: Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 2008, 28:197-213.
• [26]Saito T, Fukai A, Mabuchi A, Ikeda T, Yano F, Ohba S, et al.: Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. Nat Med 2010, 16(6):678-686.
• [27]Yang S, Kim J, Ryu JH, Oh H, Chun CH, Kim BJ, et al.: Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. Nat Med 2010, 16(6):687-693.
• [28]Sanchez M, Galy B, Muckenthaler MU, Hentze MW: Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol 2007, 14(5):420-426.
• [29]Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al.: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29(8):1039-1049.
• [30]Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15(12):1833-1840.
• [31]Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
• [32]Pincus T, Sokka T, Kautiainen H: Further development of a physical function scale on a multidimensional health assessment questionnaire (MDHAQ) for standard care of patients with rheumatic diseases. J Rheumatol 2005, 32(8):1432-1439.
• [33]Kellgren JH, Lawrence JS: Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957, 16(4):494-502.
• [34]Attur M, Belitskaya-Levy I, Oh C, Krasnokutsky S, Greenberg J, Samuels J, et al.: Increased interleukin-1beta gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum 2011, 63(7):1908-1917.
• [35]Altman RD, Gold GE: Atlas of individual radiographic features in osteoarthritis, revised. Osteoarthritis Cartilage 2007, 15(Suppl A):A1-A56.
• [36]Van den Bosch G, Van den Bossche J, Wagner C, De Schouwer P, Van De Vyvere M, Neels H: Determination of iron metabolism-related reference values in a healthy adult population. Clin Chem 2001, 47(8):1465-1467.
• [37]Milman N, Kirchhoff M: Iron stores in 1359, 30- to 60-year-old Danish women: evaluation by serum ferritin and hemoglobin. Ann Hematol 1992, 64(1):22-27.
• [38]Milman N, Kirchhoff M, Jorgensen T: Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment. Ann Hematol 1992, 65(2):96-102.
• [39]Carroll GJ, Breidahl WH, Bulsara MK, Olynyk JK: Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. Arthritis Rheum 2011, 63(1):286-294.
• [40]Carroll GJ: HFE gene mutations are associated with osteoarthritis in the index or middle finger metacarpophalangeal joints. J Rheumatol 2006, 33(4):741-743.
• [41]Cauza E, Hanusch-Enserer U, Etemad M, Koller M, Kostner K, Georg P, et al.: HFE genotyping demonstrates a significant incidence of hemochromatosis in undifferentiated arthritis. Clin Exp Rheumatol 2005, 23(1):7-12.
• [42]Rollot F, Wechsler B, du Boutin le TH, De GC, Amoura Z, Hachulla E: Hemochromatosis and femoral head aseptic osteonecrosis: a nonfortuitous association? J Rheumatol 2005, 32(2):376-378.
• [43]Ryder JJ, Garrison K, Song F, Hooper L, Skinner J, Loke Y, et al.: Genetic associations in peripheral joint osteoarthritis and spinal degenerative disease: a systematic review. Ann Rheum Dis 2008, 67(5):584-591.
• [44]Elmberg M, Hultcrantz R, Simard JF, Carlsson A, Askling J: Increased risk of arthropathies and joint replacement surgery in patients with genetic hemochromatosis: a study of 3,531 patients and their 11,794 first-degree relatives. Arthritis Care Res (Hoboken) 2013, 65:678-685.
• [45]Mazzuca SA, Brandt KD, Katz BP, Ding Y, Lane KA, Buckwalter KA: Risk factors for progression of tibiofemoral osteoarthritis: an analysis based on fluoroscopically standardised knee radiography. Ann Rheum Dis 2006, 65(4):515-519.
• [46]Samokyszyn VM, Miller DM, Reif DW, Aust SD: Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin. J Biol Chem 1989, 264(1):21-26.